The Cancer Research Institute announced that it will honor biotechnology company Regeneron, and journalist and filmmaker Perri Peltz with the 2018 Oliver R. Grace Award for Distinguished Service in Advancing Cancer Research.
FNIH has selected CRI to be its source of landscape intelligence in immuno-oncology.
Ludwig Cancer Research and the Cancer Research Institute (CRI) announce the initiation of a clinical trial to evaluate the combination of ONCOS-102, an experimental anti-tumor virotherapy, with the checkpoint blockade antibody IMFINZI® (durvalumab) for advanced ovarian and colorectal cancers.
A comprehensive, neutral analysis of the global cancer cell therapy landscape; 753 cancer cell therapies in the global development pipeline, with 375 in clinical studies
30 days of education and awareness programming for patients, caregivers, and the public about cancer immunotherapy and clinical trials
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, Floor 4 | New York, NY 10006-3111
(800) 992-2623(212) 832-9376Staff Directory
Supporters, scientists, patients, and advocates participated in CRI’s annual Wear White Day for a Future Immune to Cancer on June 14, 2019.
CRI hosted a Twitter Chat, moderated by STAT’s Sharon Begley, discussing takeaways from the ASCO19 conference last week.